EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS

Although zomepirac (ZP) and tolmetin (TM) induce anaphylactic reactions and form reactive acyl glucuronides, a direct link between the two events remains obscure. We report herein that, in addition to acyl glucuronidation, both drugs are subject to oxidative bioactivation. Following incubations of ZP with human liver microsomes fortified with NADPH and glutathione (GSH), a metabolite with an MH+ ion at m/z 597 was detected by LC/MS/MS. On the basis of collision-induced dissociation and NMR evidence, the structure of this metabolite was determined to be 5-[4′-chlorobenzoyl]-1,4-dimethyl-3-glutathionylpyrrole-2-acetic acid (ZP-SG), suggesting that the pyrrole moiety of ZP had undergone oxidation to an epoxide intermediate, followed by addition of GSH and loss of the elements of H2O to yield the observed conjugate. The oxidative bioactivation of ZP most likely is catalyzed by cytochrome P450 (P450) 3A4, since the formation of ZP-SG was reduced to ∼10% of control values following pretreatment of human liver microsomes with ketoconazole or with an inhibitory anti-P450 3A4 IgG. A similar GSH adduct, namely 5-[4′-methylbenzoyl]-1-methyl-3-glutathionylpyrrole-2-acetic acid (TM-SG), was identified when TM was incubated with human liver microsomal preparations. The relevance of these in vitro findings to the in vivo situation was established through the detection of the same thiol adducts in rats treated with ZP and TM, respectively. Taken together, these data suggest that, in addition to the formation of acyl glucuronides, oxidative metabolism of ZP and TM affords reactive species that may haptenize proteins and thereby contribute to the drug-mediated anaphylactic reactions.

[1]  R Scott Obach,et al.  Biotransformation reactions of five-membered aromatic heterocyclic rings. , 2002, Chemical research in toxicology.

[2]  R. Jacobs,et al.  Anaphylactoid reactions to tolmetin and zomepirac. , 1983, Annals of allergy.

[3]  M. Gorrell,et al.  Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. , 2001, Life sciences.

[4]  J. Lasker,et al.  Isolation of P450 enzymes from human liver. , 1991, Methods in enzymology.

[5]  T. Baillie,et al.  Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[6]  G. Aithal Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity , 2004, Expert opinion on drug safety.

[7]  W. Wu,et al.  The metabolism of zomepirac sodium. II. Isolation and identification of the urinary metabolites in rat, mouse, rhesus monkey, and man. , 1980, Drug metabolism and disposition: the biological fate of chemicals.

[8]  T. Baillie,et al.  Mass spectrometry in the analysis of glutathione conjugates. , 1993, Biological mass spectrometry.

[9]  L. Benet,et al.  Hypersensitivity to nonsteroidal anti-inflammatory drugs , 1995, Nature Medicine.

[10]  A. Munafo,et al.  Disposition and irreversible plasma protein binding of tolmetin in humans , 1988, Clinical pharmacology and therapeutics.

[11]  V. Armstrong,et al.  Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications , 2003, Therapeutic drug monitoring.

[12]  J. M. Grindel,et al.  Review of the Pharmacokinetics and Metabolism of Zomepirac in Man and Animals , 1980, Journal of clinical pharmacology.

[13]  L. Benet,et al.  Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. , 1990, The Journal of pharmacology and experimental therapeutics.

[14]  L. Benet,et al.  Irreversible binding of zomepirac to plasma protein in vitro and in vivo. , 1986, The Journal of clinical investigation.

[15]  T. Baillie,et al.  Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  A. D. Rodrigues,et al.  Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. , 1999, The Journal of pharmacology and experimental therapeutics.

[17]  H. Novey,et al.  Anaphylactoid reactions to tolmetin after interrupted dosage. , 1985, The Western journal of medicine.

[18]  E M Faed,et al.  Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. , 1984, Drug metabolism reviews.

[19]  Wei Tang,et al.  In Vitro Drug Metabolism , 2004 .

[20]  U. Boelsterli,et al.  Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. , 1993, Toxicology and applied pharmacology.

[21]  M. Bailey,et al.  Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. , 1998, Chemico-biological interactions.

[22]  P H Li,et al.  Actions of corticotropin-releasing factor or cortisol on follicle-stimulating hormone secretion by isolated pig pituitary cells. , 1993, Life sciences.

[23]  R. Boulieu,et al.  Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[24]  E. Vasilomanolakis,et al.  Anaphylactic Reaction Due to Zomepirac , 1984, Drug intelligence & clinical pharmacy.

[25]  Zhengyin Yan,et al.  DETECTION OF A NOVEL REACTIVE METABOLITE OF DICLOFENAC: EVIDENCE FOR CYP2C9-MEDIATED BIOACTIVATION VIA ARENE OXIDES , 2005, Drug Metabolism and Disposition.

[26]  L. Benet,et al.  Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? , 1992, Drug metabolism reviews.

[27]  D. Marguet,et al.  Hepatic covalent adduct formation with zomepirac in the CD26‐deficient mouse , 2002, Journal of gastroenterology and hepatology.

[28]  S. Cucinell,et al.  Metabolism of tolmetin in rat, monkey, and man. , 1975, Drug metabolism and disposition: the biological fate of chemicals.

[29]  Wei Tang The metabolism of diclofenac--enzymology and toxicology perspectives. , 2003, Current drug metabolism.

[30]  Yue Chen,et al.  IDENTIFICATION OF A NOVEL GLUTATHIONE ADDUCT OF DICLOFENAC, 4′-HYDROXY-2′-GLUTATHION-DESCHLORO-DICLOFENAC, UPON INCUBATION WITH HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.

[31]  L. Benet,et al.  Predictability of the covalent binding of acidic drugs in man. , 1993, Life sciences.